Breast Cancer in San Francisco: Disentangling Disparities at the Neighborhood Level

Alice Guan¹, Daphne Lichtensztajn¹, Debora Oh¹, Jennifer Jain¹, Li Tao¹, Robert A. Hiatt¹, Scarlett Lin Gomez², and Laura Fejerman²; for the San Francisco Cancer Initiative Breast Cancer Task Force

Abstract

Background: This study uses a novel geographic approach to summarize the distribution of breast cancer in San Francisco and aims to identify the neighborhoods and racial/ethnic groups that are disproportionately affected by this disease.

Methods: Nine geographic groupings were newly defined on the basis of racial/ethnic composition and neighborhood socioeconomic status. Distribution of breast cancer cases from the Greater Bay Area Cancer Registry in these zones were examined. Multivariable logistic regression models were used to determine neighborhood associations with stage IIB breast cancer at diagnosis. Cox proportional hazards regression was used to estimate the hazard ratios for all-cause and breast cancer–specific mortality.

Results: A total of 5,595 invasive primary breast cancers were diagnosed between January 1, 2006 and December 31, 2015. We found neighborhood and racial/ethnic differences in stage of diagnosis, molecular subtype, survival, and mortality. Patients in the Southeast (Bayview/Hunter's Point) and Northeast (Downtown, Civic Center, Chinatown, Nob Hill, Western Addition) areas were more likely to have stage IIB breast cancer at diagnosis, and those in the East (North Beach, Financial District, South of Market, Mission Bay, Potrero Hill) and Southeast were more likely to be diagnosed with triple-negative breast cancers (TNBC). Compared with other racial/ethnic groups, Blacks/African Americans (B/AA) experienced the greatest disparities in breast cancer–related outcomes across geographic areas.

Conclusions: San Francisco neighborhoods with lower socioeconomic status and larger minority populations experience worse breast cancer outcomes.

Impact: Our findings, which reveal breast cancer disparities at sub-county geographic levels, have implications for population-level health interventions.

Introduction

Breast cancer is one of the most commonly diagnosed cancers among women in the United States, accounting for one in three cancer diagnoses. It is also the second leading cause of cancer-related death among women, following lung cancer (1). From 2005–2015, new breast cancer cases in the United States increased an average of 0.3% per year (2).

Racial/ethnic disparities in breast cancer risk and survival at the national and regional level have been well documented (3, 4). However, researchers have recently begun to examine this phenomenon at sub-county geographic levels (5, 6). More granular geographic level studies offer a unique opportunity to understand the local impacts of disease and to inform the targeted development of programs and policies to address them.

Studies on breast cancer at sub-county (e.g., city) levels have revealed trends in disparities across racial/ethnic categories that are similar to those at the national level. Black or African American (B/AA) versus Non-Hispanic White (NHW) differences in breast cancer incidence and mortality have not improved over time in Chicago, Illinois (7), Memphis, Tennessee (8), and across many of the most populous cities in the United States.

To our knowledge, no recent studies have described the state of breast cancer in San Francisco, California. San Francisco, which is both a city and county with a population of approximately 880,000 (9), is unique in having one of the highest socioeconomic profiles in the United States, and through established mechanisms, among the highest breast cancer incidence rates in California (10). In 2017, the population of San Francisco had an average income of $96,265, which is the highest among the 25 largest metropolitan areas in the country (11). San Francisco is also characterized by a high degree of racial/ethnic diversity, which is particularly relevant for breast cancer burden. A plurality of the city’s population is NHW (40.5% of the population), followed by Asian American, Native Hawaiian, or Pacific Islanders (AANHPI, 36.3% of the population), Hispanics/Latinos (H/L, 15.2% of the population), B/AA (5.5% of the population) and other/mixed (5.0% of the population; ref. 12).

Building upon the work being done by the San Francisco Cancer Initiative (13), this article aims to (i) introduce a novel...
approach for describing meaningful disease burden in the city of San Francisco by establishing new geographic groupings based on racial/ethnic composition and neighborhood SES (nSES), and (ii) provide an update on the burden of breast cancer in the city, including identifying specific geographic regions that might experience disparate rates of disease.

Materials and Methods

Neighborhood definition

To investigate breast cancer disparities in San Francisco, it was necessary to define new geographic groupings of neighborhoods because most traditionally defined neighborhoods are too small to yield stable estimates of disease distribution. We opted to combine contiguous clusters of block groups based on attribute similarity on the basis of racial/ethnic composition and nSES. A series of racial/ethnic composition variables were created on the basis of the block group population being above or below the San Francisco median population proportion for each of the main racial/ethnic non-NHW groups (B/AA, H/L, and AANHPI). These variables were combined into 8 mutually exclusive categories as follows: (i) below median for all 3 groups (predominantly NHW), (ii) above median for AANHPI only, (iii) above median for B/AA only, (iv) above median for H/L only, (v) above AANHPI and B/AA median only, (vi) above AANHPI and H/L median only, (vii) above B/AA and H/L median only, and (viii) above median for all 3 groups (predominantly minority neighborhoods). We used a multi-component measure of nSES at the census block group level (14, 15). This measure incorporated the 2010 US Census and the 2007–2011 American Community Survey data on education, occupation, unemployment, household income, poverty, rent, and house values. Each block group was assigned an nSES quintile, which was then categorized into a low/high level (low is quintile 1–3 and high is quintile 4–5), based on the distribution of SES across census block groups in San Francisco.

A 16-category combined race/ethnicity-nSES variable was developed and assigned to each of the 579 inhabited block groups in San Francisco (Supplementary Table S1). The variable is developed as: (i) low nSES/below median for all three race-ethnicity groups, (ii) high nSES/below median for all three race-ethnicity groups, (iii) low nSES/above AANHPI median only, (iv) high nSES/above AANHPI median only, (v) low nSES/above B/AA only, (vi) high nSES/above B/AA only, (vii) low nSES/above H/L median only, (viii) high nSES/above H/L median only, (ix) low nSES/above AANHPI and B/AA median only, (x) high nSES/above AANHPI and B/AA median only, (xi) low nSES/above AANHPI and H/L median only, (xii) high nSES/above AANHPI and H/L median only, (xiii) low nSES/above B/AA and H/L median only, (xiv) high nSES/above B/AA and H/L median only, (xv) low nSES/above median for all 3 groups, and (xvi) high nSES/above median for all 3 groups (Supplementary Table S1). We mapped the San Francisco block groups using the combined race-ethnicity-nSES variable, and visually grouped contiguous block units to create 9 newly defined areas in San Francisco (Fig. 1). This 16-category classification was used to combine contiguous block groups into neighborhoods. For block groups with unclear neighborhood classification, adjudication was conducted via discussion and community feedback. Thus, the process was both data- and community-driven.

Breast cancer case population

Information about all breast cancers (defined by SEER Site Recode 26000) diagnosed among residents of San Francisco from January 1, 2006 to December 31, 2015 was obtained from the population-based Greater Bay Area Cancer Registry (GBACR). Available information routinely abstracted from the medical record included age at diagnosis, race/ethnicity (grouped into NHW, B/AA, H/L, AANHPI, or other/unknown), marital status, residential address at diagnosis, stage at diagnosis, tumor size (in centimeters, cm), lymph node involvement, histology, grade (I, II, III/IV, or unknown), primary source of payment (private, any public/Medicaid/military, Medicare only/Medicare + private, no insurance, and unknown), tumor marker expression status [estrogen receptor (ER) and progesterone receptor (PR)-together referred as hormone receptor (HR), and HER2], as well as initial treatment modalities [surgery, radiotherapy, and chemotherapy (endocrine therapy is under-captured in cancer registry data)]. We classified breast cancers into four mutually exclusive subtype categories: HR+/HER2- (defined as ER and/or PR-positive and HER2-negative), HR+/HER2+ (ER and/or PR-positive and HER2-positive), HR+/HER2+ (ER and PR-negative and HER2-positive), and triple-negative breast cancer (TNBC, ER, PR, and HER2-negative). The residential address at diagnosis was geocoded and assigned to a block group and one of the nine newly designed neighborhood areas. Forty-four males, 4 cases with sex coded other than male or female, 5 cases with invasive behavior but coded to in situ stage, and 7 cases with unknown address at diagnosis were excluded, resulting in a total of 5,622 cases for analysis.

Statistical analysis

Distributions of breast cancer cases by key patient and tumor characteristics within each of the newly defined areas were examined. We estimated the association between the newly defined areas and odds of stage IB+ breast cancer at diagnosis using sequential multivariable logistic regression. We chose stage IB+ as our outcome of interest because of the comparatively more burdensome treatment implications of IB+ (larger tumor and lymph node compromise) compared with cancers diagnosed at stage I or IIA. Covariates included age, race/ethnicity, nSES, insurance status, marital status, and molecular subtype, and were selected a priori. Survival analysis was limited to the first breast cancer diagnosis per patient. Cases that were diagnosed on death certificate or autopsy only (n = 25) or not microscopically confirmed (N = 53) were excluded from survival analysis. Patients with missing/unknown tumor size, diagnosis by mammography only, tumor not found, diffuse tumor, and macroscopic focus only (N = 234) were additionally excluded, for a final sample size of 5,363 for the survival analysis. Cox proportional hazards regression was used to estimate hazard ratios (HR) and corresponding associated 95% confidence intervals (CI). The multivariable model included year of diagnosis, age at diagnosis, marital status, molecular subtypes, race/ethnicity, insurance status, nSES block group quintile (specific to San Francisco), tumor size, lymph node involvement, tumor grade, and histological subtype; AJCC stage was included as underlying stratifying variable given lack of proportionality of hazards by stage, and we additionally adjusted for clustering by block group. For deceased patients, survival time was measured in days from the date of diagnosis to the date of death. For cause-specific survival analysis, patients who died of a cause other...
than breast cancer (ICD-10 = C50) were censored on the date of death. Patients were followed for vital status by linkage with vital records as of December 31, 2015. Patients alive at the study end date (December 31, 2015) were censored at this time or at the date of last follow-up (i.e., last known contact). All statistical tests were carried out using SAS software version 9.4 (SAS Institute).

Mammography prediction surfaces were created using an optimized ordinary kriging model in ArcGIS (16) based on the census tract level mammogram values from the 500 Cities Project (17). Neighborhood level estimates were derived by extracting the values from the prediction surface for 1,000 randomly placed points in each neighborhood polygon and calculating the mean. The interpolation of mammography prediction surfaces allowed for the assignment of predicted values across our newly defined geographic units.

Results

A total of 5,622 invasive primary breast cancers were diagnosed in San Francisco female residents between January 1, 2006 and December 31, 2015. Figure 1 shows the newly defined areas based on nSES and race/ethnicity composition in San Francisco. Characteristics and distribution of the breast cancer cases within the newly defined areas are shown on Table 1. There are substantial variations in the racial/ethnic distribution of breast cancer cases within specific areas compared with San Francisco overall. NHW and AANHPI made up the greatest proportion of patients in San Francisco overall (47.5% and 36.3%, respectively), but the racial/ethnic distribution of breast cancer cases varied across areas. Although 7.2% of the breast cancer cases in San Francisco were B/AA, 25.5% of the cases in the Southeast (Bayview/Hunter’s Point) were B/AA. Similarly, although 8.4% of the breast cancer cases in San Francisco were H/L, 24.8% of the cases in the Center-East (Mission and Bernal Heights) were H/L.

Compared with other areas, more cases in the East (12.4%, including North Beach, Financial District, South of Market, Mission Bay, Potrero Hill) and Southeast (11.9%) were diagnosed with a TBBC (a more aggressive molecular subtype of breast cancer). The Southeast and Northeast (Downtown, Civic Center, Chinatown, Nob Hill, Western Addition) areas had greater proportions of stage IIB+ breast cancer at diagnosis (30.3% and 29.0%, respectively), as well as unknown stage at diagnosis (3.9% and 4.3%, respectively). The Northeast area also had the highest proportion of unclassified molecular subtype (10.7%; Table 1). This is consistent with the model-based estimates for mammography use obtained from the 500 cities data, which show that the Southeast and Northeast areas have the lowest screening rates (Fig. 1).
Table 1. Distribution of race/ethnicity, nSES, stage at diagnosis, and molecular subtype by newly defined areas for female invasive breast cancer cases diagnosed in San Francisco, 2006–2015

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>NHW</td>
<td>2,673 (47.5%)</td>
<td>290 (56.8%)</td>
<td>424 (69.1%)</td>
<td>121 (36.7%)</td>
<td>219 (62.9%)</td>
<td>116 (19.7%)</td>
<td>236 (29.1%)</td>
<td>16 (9.7%)</td>
<td>369 (42.4%)</td>
<td>519 (77.3%)</td>
</tr>
<tr>
<td>B/AA</td>
<td>404 (7.2%)</td>
<td>17 (3.3%)</td>
<td>23 (3.7%)</td>
<td>15 (4.5%)</td>
<td>18 (5.2%)</td>
<td>150 (25.5%)</td>
<td>57 (7.0%)</td>
<td>12 (1.4%)</td>
<td>18 (2.7%)</td>
<td>94 (10.7%)</td>
</tr>
<tr>
<td>H/L</td>
<td>475 (8.4%)</td>
<td>31 (6.1%)</td>
<td>41 (6.7%)</td>
<td>82 (24.8%)</td>
<td>34 (9.8%)</td>
<td>80 (13.6%)</td>
<td>102 (12.6%)</td>
<td>30 (3.4%)</td>
<td>28 (4.2%)</td>
<td>47 (5.3%)</td>
</tr>
<tr>
<td>AANHPI</td>
<td>2,043 (36.3%)</td>
<td>171 (33.5%)</td>
<td>121 (19.7%)</td>
<td>110 (33.3%)</td>
<td>74 (21.3%)</td>
<td>239 (40.6%)</td>
<td>411 (50.7%)</td>
<td>458 (52.6%)</td>
<td>104 (15.5%)</td>
<td>355 (40.4%)</td>
</tr>
<tr>
<td>Other/unknown</td>
<td>27 (0.5%)</td>
<td>a</td>
<td>a</td>
<td>a</td>
<td>a</td>
<td>a</td>
<td>a</td>
<td>a</td>
<td>a</td>
<td>a</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1,133 (20.2%)</td>
<td>a</td>
<td>a</td>
<td>71 (21.5%)</td>
<td>123 (3.4%)</td>
<td>384 (64.8%)</td>
<td>224 (27.7%)</td>
<td>a</td>
<td>a</td>
<td>445 (50.6%)</td>
</tr>
<tr>
<td>2</td>
<td>1,224 (21.8%)</td>
<td>a</td>
<td>&lt;5 (0.5%)</td>
<td>169 (11.2%)</td>
<td>153 (7.7%)</td>
<td>122 (20.7%)</td>
<td>448 (55.3%)</td>
<td>222 (25.5%)</td>
<td>12 (1.8%)</td>
<td>235 (26.7%)</td>
</tr>
<tr>
<td>3</td>
<td>1,127 (20.0%)</td>
<td>59 (11.5%)</td>
<td>81 (13.2%)</td>
<td>84 (23.5%)</td>
<td>a</td>
<td>85 (14.5%)</td>
<td>133 (16.4%)</td>
<td>481 (55.2%)</td>
<td>34 (5.1%)</td>
<td>170 (19.3%)</td>
</tr>
<tr>
<td>4</td>
<td>1,053 (18.7%)</td>
<td>234 (45.8%)</td>
<td>237 (36.6%)</td>
<td>a</td>
<td>152 (43.7%)</td>
<td>a</td>
<td>5 (0.6%)</td>
<td>148 (17.0%)</td>
<td>261 (33.9%)</td>
<td>16 (1.8%)</td>
</tr>
<tr>
<td>5</td>
<td>1,085 (19.3%)</td>
<td>218 (42.7%)</td>
<td>293 (47.7%)</td>
<td>6 (1.8%)</td>
<td>171 (49.1%)</td>
<td>a</td>
<td>a</td>
<td>20 (2.3%)</td>
<td>364 (54.2%)</td>
<td>15 (3.5%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>61.07 (14.81)</td>
<td>70.64 (15.6)</td>
<td>56.56 (14.4)</td>
<td>59.48 (15.9)</td>
<td>61.2 (13.8)</td>
<td>61.54 (14.92)</td>
<td>61.82 (15.37)</td>
<td>63.32 (14.76)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I-IIa</td>
<td>4,022 (71.5%)</td>
<td>382 (74.8%)</td>
<td>433 (70.5%)</td>
<td>232 (70.3%)</td>
<td>254 (73.0%)</td>
<td>387 (65.8%)</td>
<td>596 (73.8%)</td>
<td>632 (72.6%)</td>
<td>518 (77.2%)</td>
<td>586 (66.7%)</td>
</tr>
<tr>
<td>Stage IIb and higher</td>
<td>1,430 (25.4%)</td>
<td>116 (22.7%)</td>
<td>165 (26.9%)</td>
<td>87 (26.4%)</td>
<td>88 (23.3%)</td>
<td>178 (30.3%)</td>
<td>193 (23.8%)</td>
<td>210 (24.1%)</td>
<td>138 (20.6%)</td>
<td>255 (29.0%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HR⁺/HER2⁺</td>
<td>3,785 (67.3%)</td>
<td>364 (71.2%)</td>
<td>438 (71.3%)</td>
<td>223 (67.0%)</td>
<td>237 (66.8%)</td>
<td>388 (64.8%)</td>
<td>521 (64.3%)</td>
<td>607 (69.7%)</td>
<td>474 (70.6%)</td>
<td>542 (61.7%)</td>
</tr>
<tr>
<td>HR⁺/HER2⁺</td>
<td>565 (10.0%)</td>
<td>40 (7.8%)</td>
<td>56 (9.1%)</td>
<td>40 (12.1%)</td>
<td>37 (10.6%)</td>
<td>59 (10.0%)</td>
<td>91 (11.2%)</td>
<td>73 (8.4%)</td>
<td>64 (9.5%)</td>
<td>105 (11.9%)</td>
</tr>
<tr>
<td>HR⁺/HER2⁺</td>
<td>296 (53.5%)</td>
<td>21 (41%)</td>
<td>28 (4.6%)</td>
<td>15 (4.5%)</td>
<td>15 (4.5%)</td>
<td>36 (6.1%)</td>
<td>43 (3.3%)</td>
<td>51 (3.9%)</td>
<td>26 (3.9%)</td>
<td>61 (6.9%)</td>
</tr>
<tr>
<td>TNBC</td>
<td>540 (9.6%)</td>
<td>42 (8.2%)</td>
<td>52 (8.5%)</td>
<td>35 (10.6%)</td>
<td>43 (12.4%)</td>
<td>70 (10.9%)</td>
<td>86 (10.6%)</td>
<td>81 (9.3%)</td>
<td>54 (8.0%)</td>
<td>77 (8.8%)</td>
</tr>
<tr>
<td>Unclassified</td>
<td>436 (7.8%)</td>
<td>44 (8.6%)</td>
<td>40 (6.5%)</td>
<td>19 (5.8%)</td>
<td>16 (4.6%)</td>
<td>42 (7.1%)</td>
<td>69 (8.5%)</td>
<td>59 (6.8%)</td>
<td>53 (7.9%)</td>
<td>94 (10.7%)</td>
</tr>
</tbody>
</table>

*Suppressed due to n<5.
B/AA patients with breast cancer have the highest proportion of TNBC (20.0%, compared with 8.2%, 11.6%, and 9% in NHW, H/L, and AANHPI; Supplementary Fig. S1). The proportion of B/AA patients diagnosed with TNBC is high across all San Francisco areas, even those with low proportions of B/AA residents (33.3%, 19.3%, and 21.3% in the East, Southwest, and Northeast areas; Supplementary Table S2).

The survival analyses were limited to microscopically confirmed first primary breast tumors not reported on death certificate only, resulting in 5,363 patients with breast cancer. The lowest 5-year breast cancer specific survival rates were observed in the Northeast (rate 88.5; 95% CI, 85.6–90.9), Center-South (rate 89.7; 95% CI, 86.4–92.2), and Southeast (rate 89.7; 95% CI, 86.1–92.4). Compared with other racial ethnic groups, B/AA patients diagnosed with TNBC experience the greatest proportion of TNBC diagnosis across all neighborhoods, as well as the worst 5-year overall and breast cancer–specific survival. H/L and AANHPI communities experience disparities as well, but differences are less marked than those between B/AA and NHW.

Ongoing research suggests that disparities observed in tumor subtype distribution between B/AA and NHW could be due, in part, to genetics (19). There is also evidence that some lifestyle factors, such as number of full-term pregnancies, contribute to disparities in breast cancer outcomes (20). Our study introduces an innovative approach to describe the burden of cancer at a sub-county level. Our findings reveal that, similar to other regions across the United States, women who reside in low SES areas with larger representation of minority populations are diagnosed with more advanced and aggressive breast cancer and have lower survival than women who reside in high SES NHW neighborhoods (18). In particular, although B/AA make up only 7.2% of all breast cancer cases between 2006 and 2015, they experienced the greatest proportion of TNBC diagnosis (50.9%; 95% CI, 1.16–2.02) of having a stage IIB diagnosis (Table 3 and Supplementary Table S5).

The survival analyses were limited to microscopically confirmed first primary breast tumors not reported on death certificate only, resulting in 5,363 patients with breast cancer. The lowest 5-year breast cancer specific survival rates were observed in the Northeast (rate 88.5; 95% CI, 85.6–90.9), Center-South (rate 89.7; 95% CI, 86.4–92.2), and Southeast (rate 89.7; 95% CI, 86.1–92.4). Compared with other racial ethnic groups, B/AA patients diagnosed with TNBC experience the greatest proportion of TNBC diagnosis across all neighborhoods, as well as the worst 5-year overall and breast cancer–specific survival. H/L and AANHPI communities experience disparities as well, but differences are less marked than those between B/AA and NHW.

Ongoing research suggests that disparities observed in tumor subtype distribution between B/AA and NHW could be due, in part, to genetics (19). There is also evidence that some lifestyle factors, such as number of full-term pregnancies.
and breastfeeding are associated with risk of TNBC and could also explain the higher incidence of TNBC in B/AA women (20, 21). The particular tumor subtype distribution in H/L and AANHPI could also be partly due to differences in genetics and environmental/lifestyle exposures that impact tumor biology (22, 23). However, the overlap between stage at diagnosis and screening rates in the different areas of San Francisco (Fig. 2) strongly suggest that the observed disparity in stage at diagnosis and its impact on breast cancer survival and quality of life could be addressed, at least in part, by closing the gap in screening rates between women in different areas of the city.

Although several studies have suggested that improving access to high-quality care and follow-up in patients from low SES areas is likely to reduce survival disparities (24, 25), simply increasing access may not be sufficient for eliminating racial differences (18, 26, 27). In fact, although health care for all has been available in San Francisco since 2007 (28), in meetings of the SF CAN Breast Cancer Task Force, community representatives from underserved communities report that they do not generally know about this. The disproportional burden of unknown stage at diagnosis and unclassified molecular subtype may reflect the quality of care that individuals in certain SF areas receive. Similar to other metropolitan cities in the United States (29, 30), structural racism could be a contributing factor to disparities among B/AA women in San Francisco.

Even after accounting for the effect of age, race/ethnicity, nSES, insurance type, marital status, and clinical features, living in the Center-East area is still associated with increased odds of stage IIB+ cancer at diagnosis. The Center-East comprises the Castro district, which has historically served as a safe haven for sexual and gender minority (SGM) populations. There is some evidence suggesting higher risk of breast cancer and mortality among lesbian and bisexual women (31, 32), but results are inconsistent, in large part due to lack of data (e.g., no data on sexual gender minority status in cancer registries). Considering the large population and diversity of SGM status within the city, San Francisco could be an ideal location to further investigate the relationship between gender identity, sexual orientation, and breast cancer risk and mortality, and to tailor interventions toward non-heterosexual women. Incorporation of sexual gender minority data into population-based cancer registries will be crucial to better document the burden of cancer in this underserved population (33, 34).

One of the limitations of our current study is the inability to produce neighborhood level incidence estimates. Using block groups as a building block provided the fine granularity to define areas with meaningful specificity. However, as population estimates required to compute incidence and mortality rates are available at the census tract level, not at the block group level, we were unable to calculate incidence rates for the 9 areas. Our recommendation for future studies is to use census tracts as the building blocks if the intent is to calculate disease rates requiring population denominators. An additional limitation in our study is the small number of breast cancer–specific deaths, which could have contributed to the lack of significant associations for breast cancer specific mortality across neighborhoods. In addition, because the San Francisco population is rapidly changing, our description based on most recently available cancer registry data may not be an accurate picture of the current burden of breast cancer in the city. Specifically, as the economic and technological landscape continues to expand, it will be critical to continue monitoring breast cancer disparities due to both racial/ethnic and socioeconomic inequity. Finally, although data are available on neighborhood-level attributes that may potentially account for some of the observed neighborhood-level disparities, the intent of this analysis was to provide a descriptive examination of the burden of breast cancer across the city. We recognize, however, the importance of providing neighborhood-level data to stakeholders and, as such, have extended this work to develop a statewide tool that allows interactive query and mapping of cancer incidence rates alongside population-level sociodemographic and behavioral risk factors (www.californiahealthmaps.org).

Given what our research has revealed regarding breast cancer health disparities in San Francisco, our present challenge will be to design programs and interventions that could more effectively promote breast cancer–preventive behaviors and access to appropriate care among the city’s most affected racial/ethnic groups. This work is being undertaken by the San Francisco Cancer Initiative’s Breast Cancer Task Force. Specifically, the Task Force will be focusing on the design and implementation of programs tailored toward AA/B, H/L, and AANHPI populations in San Francisco, with the long-term goal of reducing observed disparities in stage at diagnosis and survival. Ongoing programs, based on community feedback and evidence of efficacy, include the compilation and distribution of information about resources and services that are already available to support breast health–related practices among women in San Francisco (35–37), and the implementation of a high school student–based breast cancer awareness and education program to promote screening and health behavior change in their communities (38–41). We plan

---

**Table 4.** HRs and 95% CIs for female invasive breast cancer cases living in San Francisco, 2006–2015

<table>
<thead>
<tr>
<th>Area</th>
<th>Deaths, N</th>
<th>Model 1 (univariable)</th>
<th>Model 2 (+ age)</th>
<th>Model 3 (+ nSES)</th>
<th>Model 4 (+ race/ethnicity)</th>
<th>Full model*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Center-South</td>
<td>38</td>
<td>1.55 (0.97–2.47)</td>
<td>1.52 (0.96–2.43)</td>
<td>1.55 (0.97–2.47)</td>
<td>1.53 (0.95–2.44)</td>
<td>1.23 (0.76–2.01)</td>
</tr>
<tr>
<td>Center-West</td>
<td>40</td>
<td>1.37 (0.86–2.17)</td>
<td>1.43 (0.90–2.26)</td>
<td>1.48 (0.93–2.34)</td>
<td>1.46 (0.92–2.31)</td>
<td>1.04 (0.65–1.67)</td>
</tr>
<tr>
<td>Center-East</td>
<td>18</td>
<td>1.75 (0.63–2.04)</td>
<td>1.22 (0.69–2.16)</td>
<td>1.33 (0.66–2.69)</td>
<td>1.32 (0.65–2.68)</td>
<td>1.29 (0.63–2.64)</td>
</tr>
<tr>
<td>East</td>
<td>17</td>
<td>1.00 (0.56–1.79)</td>
<td>1.10 (0.63–2.00)</td>
<td>1.09 (0.60–1.95)</td>
<td>1.04 (0.58–1.88)</td>
<td>0.77 (0.42–1.43)</td>
</tr>
<tr>
<td>Southeast</td>
<td>49</td>
<td>1.70 (1.09–2.64)</td>
<td>1.78 (1.14–2.77)</td>
<td>1.72 (0.89–3.14)</td>
<td>1.83 (0.70–3.25)</td>
<td>1.00 (0.52–1.90)</td>
</tr>
<tr>
<td>Southwest</td>
<td>49</td>
<td>1.05 (0.74–1.78)</td>
<td>1.16 (0.75–1.80)</td>
<td>1.24 (0.67–2.29)</td>
<td>1.17 (0.63–2.17)</td>
<td>0.94 (0.50–1.74)</td>
</tr>
<tr>
<td>West</td>
<td>56</td>
<td>1.26 (0.82–1.94)</td>
<td>1.25 (0.82–1.93)</td>
<td>1.61 (0.96–2.72)</td>
<td>1.64 (0.97–2.79)</td>
<td>1.16 (0.67–1.99)</td>
</tr>
<tr>
<td>North</td>
<td>33</td>
<td>Ref</td>
<td>Ref</td>
<td>Ref</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>Northeast</td>
<td>75</td>
<td>1.82 (1.21–2.74)</td>
<td>1.74 (1.15–2.62)</td>
<td>1.74 (0.97–3.12)</td>
<td>1.69 (0.94–3.04)</td>
<td>1.22 (0.68–2.19)</td>
</tr>
</tbody>
</table>

NOTE: The numbers in bold indicate statistical significance at the 5% level.

*Full model includes area, age, nSES, race/ethnicity, marital status, insurance, molecular subtype, stage (as a stratification variable), grade, surgery, radiotherapy, and chemotherapy.
Figure 2. Distribution of mammography and stage II B⁺ cancer at diagnosis in San Francisco. A, Model-based estimates for mammography use among women ages 50 to 74 years, 2016. B, Proportion of cases with stage II B⁺ cancer at diagnosis.
to monitor changes in geographic burden over time and document potential impacts of these and future programs.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Disclaimer
The ideas and opinions expressed herein are those of the author(s) and do not necessarily reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their contractors and subcontractors.

Authors’ Contributions
Conception and design: R.A. Hiatt, S.L. Gomez, L. Fejerman
Development of methodology: S.L. Gomez, L. Fejerman
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S.L. Gomez
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): D. Lichtensztajn, D. Oh, J. Jain, L. Tao, R.A. Hiatt, S.L. Gomez, L. Fejerman
Writing, review, and/or revision of the manuscript: A. Guan, D. Lichtensztajn, D. Oh, R.A. Hiatt, S.L. Gomez, L. Fejerman
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L. Tao, S.L. Gomez
Study supervision: R.A. Hiatt, S.L. Gomez, L. Fejerman

Acknowledgments
The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries, under cooperative agreement 5NU5DP006344; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract HHSN261201800032I awarded to the University of California, San Francisco, contract HHSN261201800015I awarded to the University of Southern California; and contract HHSN2612018000091 awarded to the Public Health Institute, Cancer Registry of Greater California. The authors acknowledge the following members of the SF CAN Breast Cancer Task Force: Becky Mark, Carol Simmons, Catherine Thomsen, Cecilia Thomas, Fern Orenstein, Galen Joseph, Judith Bilenkikoff Harkins, Alyssa Nickel, Niharika Dixit, Olivia Fe, Kylie Cooper, Vivian Lee, Leichun Fung, Janice Barlow, Lawra van ’t Veer, Jeffery A. Tiee, Roberto Vargas, Carmen Ortiz, and Kaya Balke. This research was funded by the Helen Diller Comprehensive Cancer Center at the University of California, San Francisco through the San Francisco Cancer Initiative.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 10, 2019; revised August 30, 2019; accepted September 20, 2019; published first September 23, 2019.

References

Cancer Epidemiol Biomarkers Prev; 28(12) December 2019

www.aacrjournals.org

Breast Cancer in San Francisco

Cancer Epidemiol Biomarkers Prev; 28(12) December 2019

1975

Downloaded from cebp.aacrjournals.org on February 6, 2021. © 2019 American Association for Cancer Research.
Breast Cancer in San Francisco: Disentangling Disparities at the Neighborhood Level

Alice Guan, Daphne Lichtensztajn, Debora Oh, et al.


Updated version: Access the most recent version of this article at:
doi:10.1158/1055-9965.EPI-19-0799

Supplementary Material: Access the most recent supplemental material at:
http://cebp.aacrjournals.org/content/suppl/2019/09/21/1055-9965.EPI-19-0799.DC1

Cited articles: This article cites 31 articles, 4 of which you can access for free at:
http://cebp.aacrjournals.org/content/28/12/1968.full#ref-list-1

E-mail alerts: Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions: To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions: To request permission to re-use all or part of this article, use this link http://cebp.aacrjournals.org/content/28/12/1968. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.